Skip to Content

Alpha 1-Proteinase Inhibitor Dosage

Medically reviewed on June 12, 2017.

Applies to the following strengths: human

Usual Adult Dose for Alpha-1 Proteinase Inhibitor Deficiency

Chronic augmentation and maintenance therapy in patients with clinical evidence of emphysema: 60 mg/kg via IV infusion once a week

Infusion rates:
Aralast(TM), Aralast NP(TM), Prolastin(R), Prolastin(R)-C, Zemaira(R): Should be administered at a rate not exceeding 0.08 mL/kg per minute
Glassia(TM): Should be administered at a rate not exceeding 0.04 mL/kg per minute

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


Alpha 1-proteinase inhibitor is contraindicated in individuals with selective IgA deficiencies who have known antibodies against IgA. Such individuals may experience severe reactions, including anaphylaxis, to IgA, which may be present in alpha 1-proteinase inhibitor preparations.

The rate of administration should be monitored closely, at least until the physician has had sufficient experience with a given patient. Vital signs should be monitored continuously and the patient should be carefully observed throughout the infusion. If anaphylactic or severe anaphylactoid reactions occur, the infusion should be discontinued immediately. Epinephrine and other appropriate supportive therapy should be available for the treatment of any acute anaphylactic or anaphylactoid reaction.

Alpha 1-proteinase inhibitor should be used with caution in patients at risk for circulatory overload. As with any colloid solution, there may be an increase in plasma volume following IV administration.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

Aralast(TM), Aralast NP(TM), Prolastin(R), Prolastin(R)-C, and Zemaira(R) should be administered within 3 hours following reconstitution. Drug and diluent should be at room temperature before reconstitution.

Glassia(TM) should be administered at room temperature within 3 hours of entering the vials.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.